NCT04422990

Brief Summary

The purpose of this clinical study is to evaluate the safety and performance of an investigational soft contact lens compared to a commercially available soft contact lens when worn in a daily wear modality.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
158

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

14 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 5, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 9, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

October 1, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 22, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 18, 2021

Completed
9 months until next milestone

Results Posted

Study results publicly available

February 24, 2022

Completed
Last Updated

March 29, 2022

Status Verified

March 1, 2022

Enrollment Period

5 months

First QC Date

June 5, 2020

Results QC Date

February 3, 2022

Last Update Submit

March 3, 2022

Conditions

Keywords

Vision CorrectionContact Lens

Outcome Measures

Primary Outcomes (1)

  • Least Squares Mean Contact Lens Corrected Distance Visual Acuity (CLCDVA) at Week 1 Follow-Up

    Visual acuity (VA) was assessed for each eye individually with study lenses in place using a letter chart. VA was collected in Snellen and converted to logarithm minimum angle of resolution (logMAR). A logMAR value of 0 equates to 20/20 Snellen visual acuity (normal distance eyesight), with lower logMAR values indicating better visual acuity.

    Week 1 Follow-Up

Secondary Outcomes (1)

  • Percentage of Subjects Achieving CLCDVA 20/20 or Better in Each Eye at Week 1 Follow-Up

    Week 1 Follow-Up

Study Arms (2)

LID018869

EXPERIMENTAL

Lehfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.

Device: Lehfilcon A contact lensesDevice: CLEAR CARE

Biofinity

ACTIVE COMPARATOR

Comfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.

Device: Comfilcon A contact lensesDevice: CLEAR CARE

Interventions

Investigational silicone hydrogel contact lenses

Also known as: LID018869
LID018869

Commercially available silicone hydrogel contact lenses

Also known as: CooperVision® BIOFINITY®, Biofinity
Biofinity

Hydrogen peroxide-based contact lens cleaning and disinfecting solution

BiofinityLID018869

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Successful wear of spherical daily wear frequent replacement soft contact lenses for distance correction in both eyes during the past 3 months for a minimum of 5 days per week and 8 hours per day;
  • Manifest cylinder equal to or less than 0.75 diopter (D) in each eye;
  • Best spectacle corrected visual acuity (using manifest refraction) of 20/20 or better in each eye;

You may not qualify if:

  • Wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment;
  • Habitually wearing Biofinity lenses;
  • Monovision or multifocal contact lens wearers;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

Alcon Investigative Site

Los Angeles, California, 90012, United States

Location

Alcon Investigative Site

Novato, California, 94945, United States

Location

Alcon Investigative Site

Oakland, California, 94513, United States

Location

Alcon Investigative Site

Oakland, California, 94607, United States

Location

Alcon Investigative Site

San Francisco, California, 94122, United States

Location

Alcon Investigative Site

Orlando, Florida, 32803, United States

Location

Alcon Investigative Site

West Palm Beach, Florida, 33405, United States

Location

Alcon Investigative Site

Downers Grove, Illinois, 60515, United States

Location

Alcon Investigative Site

Louisville, Kentucky, 40221, United States

Location

Alcon Investigative Site

New York, New York, 10036, United States

Location

Alcon Investigative Site

Cleveland, Ohio, 44106, United States

Location

Alcon Investigative Site

Boiling Springs, South Carolina, 29316, United States

Location

Alcon Investigative Site

Plano, Texas, 75093, United States

Location

Alcon Investigative Site

Wichita Falls, Texas, 76308, United States

Location

MeSH Terms

Conditions

Refractive Errors

Condition Hierarchy (Ancestors)

Eye Diseases

Results Point of Contact

Title
CDMA Project Lead, Vision Care
Organization
Alcon Research, LLC

Study Officials

  • Sr. Clinical Trial Lead, CDMA Vision Care

    Alcon Research, LLC

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 5, 2020

First Posted

June 9, 2020

Study Start

October 1, 2020

Primary Completion

February 22, 2021

Study Completion

May 18, 2021

Last Updated

March 29, 2022

Results First Posted

February 24, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share

Locations